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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S252Figure 1. Presentation of the mean values of the KOOS subscales for different grades of
radiographic changes in the right knee joint (n¼302). Normative values are age
matched values from Paradowski et al. 2006.
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IMPACT OF PREDICTABLE VERSUS UNPREDICTABLE INTERMITTENT
PAIN ON SOCIAL ROLE PARTICIPATION IN SUBJECTS WITH KNEE
OSTEOARTHRITIS
T. Kendzerska y,z, M. Gignac y,x, I. Stanaitis z, G. Hawker y,z. yUniv. of
Toronto, Toronto, ON, Canada; zWomen's Coll. Hosp., Toronto, ON,
Canada; x Toronto Western Res. Inst., Toronto, ON, Canada
Purpose: Focus group discussions in individuals with hip/knee osteo-
arthritis (OA) identiﬁed two types of OA pain - a constant background
pain and a less frequent, but more intense and often unpredictable,
intermittent pain - with the latter having the greatest impact on social
role participation. These ﬁndings led to the creation of the OARSI-
OMERACT measure of Intermittent and Constant OA Pain (ICOAP). The
current study sought to validate focus group ﬁndings with respect to the
inﬂuence of OA pain predictability on participation restrictions.
Methods: In an established community cohort aged 50+ years with hip/
knee OA, we assessed demographic characteristics, OA pain (ICOAP
Knee) and disability (KOOS-PS), and participation restrictions. ICOAP is
comprised of two subscales: a 5-item scale assesses constant pain and
a 6-item scale assesses intermittent pain, or ‘pain that comes and goes’.
Subscale scores are created by summing item scores and transforming
to 0-100; higher scores indicate greater pain. Those with intermittent
pain were asked to report the frequency with which the pain occurs
‘without warning’ (i.e., unpredictably) and ‘after a trigger’ (i.e.,
predictably), from 0 (never) to 4 (very often). To assess social role
participation, participants were asked the degree to which they had
given up or limited time spent in important roles due to their hip/knee
arthritis, from 1, not at all, to 5, a great deal. Logistic regressionwas used
to examine the effect of the frequent unpredictable and frequent
predictable intermittent knee pain (often/very often - yes/no) on
participation restrictions (roles restricted quite a bit/a great deal - yes/
no), controlling for age, gender, and OA severity (ICOAP subscale scores;
KOOS-PS score). Speciﬁcally, we assessed for interactions between
ICOAP intermittent scores and each of frequent unpredictable and
predictable knee pain on social role restrictions.
Results: 265 cohort participants with complete datawere included in our
analyses. Theirmean agewas 65 years (SD 10) and 75%were female. 69.6%
reported intermittent knee pain only, 22.5% constant knee pain only, and
7.9%bothpain types.Median (IQR) ICOAP intermittent and constant scores
were 37.5 (20.8-45.8) and 0 (0), respectively. Of the 186 subjects who re-
ported intermittent pain, 14.6% reported frequent unpredictable pain and
10.9% reported frequent predictable pain. 40% and 36.6% had limited time
spent in ‘important roles’ ‘somewhat’ or ‘quite a bit’. Controlling for age,
sex, ICOAPsubscale andKOOS-PS scores,we found a signiﬁcant interaction
between ICOAP intermittent pain severity and frequency of unpredictable
pain on participation restrictions (p¼0.03), such that for individuals with
similar levels of intermittent pain severity, the impact on social role
participationwasgreater for thosewithmore frequent versus less frequent
unpredictable intermittent pain. No interaction was found between
intermittent pain severity and frequent predictable pain.
Conclusion: Our results conﬁrm ﬁndings from qualitative research that,
controlling for other factors, social role restrictions are greatest among
those with intermittent knee pain that frequently occurs warning
inﬂuences. Further studies in larger cohorts, and with greater variability
in pain types, is warranted to conﬁrm our ﬁndings and, if conﬁrmed, to
elucidate potential explanations.481
EFFICACY AND TOLERABILITY OF CELECOXIB AND NAPROXEN VS
PLACEBO IN HISPANIC PATIENTS WITH KNEE OSTEOARTHRITIS
M.N. Essex, R. Behar, M.A. O'Connell, P. Bhadra Brown. Pﬁzer Inc., New
York, NY, USA
Purpose: The primary objective of this study was to determine if cel-
ecoxib 200 mg once daily (qd) was as effective as naproxen 500 mg
twice daily (bid) in the treatment of osteoarthritis (OA) of the knee in
Hispanic patients.
Methods: Hispanic patients aged 45 years with diagnosed knee OA in
a ﬂare state and with a functional capacity classiﬁcation of I to III were
randomized in a 2:2:1 manner to receive celecoxib 200 mg qd, nap-
roxen 500 mg bid, or placebo for 6 weeks. The primary efﬁcacy variable
was the change in the Patient's Assessment of Arthritis Pain at 6 weeks
compared with baseline. Secondary efﬁcacy variables were change in
Patient's and Physician's Global Assessments of Arthritis from baseline
to Week 6/early termination, change in Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) scores from baseline to
Week 6/early termination, change in American Pain Society pain scores,
score on Pain Satisfaction Scale, Patient Health Questionnaire (PHQ-9)
responses, and measurement of upper GI (UGI) tolerability.
Results: 318 subjects were randomized; 239 completed the trial (96
celecoxib, 96 naproxen, 47 placebo) and formed the primary analysis
population. Celecoxib was observed to be as effective as naproxen in
reducing OA pain (least squares mean change from baseline -39.7,
standard error [SE] 2.7 for celecoxib, -36.9, SE 2.6 for naproxen; the
lower bound of the 2-sided 95% conﬁdence interval for the treatment
difference [naproxen-celecoxib] was above -10 mm). Similar efﬁcacy
was seen for celecoxib and naproxen in secondary outcomes. No
statistically signiﬁcant differences between celecoxib and naproxen
groups were seen on the Patient's or Physician's Global Assessments of
Arthritis, WOMAC Index scores, UGI, Pain Satisfaction Scale score, and
PHQ-9. The incidence of adverse events (AE) and treatment-related AEs
was similar among treatment groups. 13 subjects withdrew from the
study due to AEs (3 celecoxib, 9 naproxen, 1 placebo); 10 discontinued
due to treatment-related AEs (2 celecoxib, 7 naproxen, 1 placebo). UGI
events (moderate or severe nausea, abdominal pain, and/or dyspepsia)
were reported by 3 celecoxib, 4 naproxen, and 1 placebo subject. One
subject in the naproxen group had a GI hemorrhage; this was consid-
ered a treatment-related AE and resulted in withdrawal from the study.
Conclusions: Celecoxib 200 mg qdwas as effective as naproxen 500mg
bid in the treatment of signs and symptoms of knee OA in Hispanic
subjects. Celecoxibwas shown to be safe andwell tolerated in this study
population. This information may be of use to physicians treating
Hispanic patients with OA.482
RESPONSE TO NONSTEROIDAL ANTI-INFLAMMATORY AGENTS IN
ASIAN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE
M.N. Essex, M.A. O'Connell, R. Behar, P. Bhadra Brown. Pﬁzer Inc, New
York, NY, USA
Purpose: Celecoxib is an effective treatment for osteoarthritis (OA);
however, its efﬁcacy and safety proﬁle has not been extensively studied
in different ethnic populations. Differences in therapeutic response to
pharmacologic agents have been found in the Asian population, but
there are limited data for OA treatments. This study was designed to
compare analgesic efﬁcacy, tolerability, and safety of celecoxib, nap-
roxen, and placebo in an Asian American population with OA of the
knee.
Methods: Eligible patients in this 6-week, multicenter, randomized,
double-blind, placebo-controlled, parallel-group study were aged  45
years, of self-reported Asian descent, and with OA of the knee in a ﬂare
state and a functional capacity classiﬁcation of I to III. Patients were
randomized to 1 of 3 regimens: celecoxib 200 mg once daily (qd),
naproxen 500 mg twice daily (bid), or placebo, in a 2:2:1 ratio. The
primary efﬁcacy variable was the change in the Patient's Assessment of
Arthritis Pain at Week 6 compared with baseline using a 100 mm visual
analog scale (VAS). Secondary efﬁcacy variables included Patient's and
Physician's Global Assessment of Arthritis, Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC), Pain Satisfaction
Scale, Patient Health Questionnaire (PHQ-9), and American Pain Society
(APS) pain scores. Other secondary variables included evaluations of
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moderate to severe event of nausea, abdominal pain, or dyspepsia.
Results: 362 patients were randomized and received treatment; 81
discontinued prematurely (27 celecoxib, 37 naproxen, 17 placebo), and
286 were included in the efﬁcacy valuable population (121 celecoxib,
107 naproxen, 58 placebo). Patient ages ranged from 42 to 90 years,
with means of 65.9, 64.1, and 63.9 years for celecoxib, naproxen, and
placebo, respectively. Most patients were female (67%-68%). Mean
duration of OA was 4.5, 4.8, and 4.6 years for celecoxib, naproxen, and
placebo, respectively, with a range of 0.1 to 38.0 years. Mean changes in
Patient's Assessment of Arthritis Pain (VAS) from baseline to Week 6/
early terminationwere -37 mm, -38 mm, and -34 mm for the celecoxib,
naproxen, and placebo treatment groups, respectively. For the primary
end point, celecoxib was observed to be as effective as naproxen in
reducing OA pain (difference in least squares means -0.4, standard error
2.5, 95% conﬁdence interval -5.2 to 4.5). No statistically signiﬁcant
differences were observed between celecoxib and naproxen in the
Patient's and Physician's Global Assessment of Arthritis, theWOMACOA
Index scores, UGI tolerability, the Pain Satisfaction Scale, and the PHQ-9.
UGI events, speciﬁcally, moderate or severe nausea, abdominal pain,
and/or dyspepsia, were experienced by 16 patients (5/145 [3%] in the
celecoxib group, 9/141 [6%] in the naproxen group, and 2/76 [3%] in the
placebo group). No statistically signiﬁcant differences in UGI tolerability
were observed among the treatment groups.
Conclusions: Celecoxib 200 mg qd was as effective as naproxen 500mg
bid in the treatment of the signs and symptoms of OA of the knee in
Asian American patients in a trial designed to evaluate this population
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EFFICACY AND TOLERABILITY OF CELECOXIB IN PATIENTS WITH
OSTEOARTHRITIS WHO PREVIOUSLY DID NOT RESPOND TO OR DID
NOT TOLERATE NAPROXEN AND IBUPROFEN: RESULTS FROM 2
IDENTICALLY DESIGNED RANDOMIZED TRIALS
M.J. Asmus y, M.N. Essex z, P. Bhadra Brown z, S.R. Mallen z. y Pﬁzer Inc,
Middleton, WI, USA; z Pﬁzer Inc, New York, NY, USA
Purpose: The purpose of these 2 identically designed studies (Study 1,
Study 2) was to compare the efﬁcacy and safety of celecoxib 200 mg
once daily (qd) with placebo in patients with osteoarthritis (OA) of the
knee who previously were nonresponsive to or did not tolerate treat-
ments with both naproxen and ibuprofen (prescription strength).
Methods: Both trials were 6-week randomized, double-blind, parallel-
group, placebo-controlled, multicenter concurrent trials. Patients aged
 40 years with active symptomatic OA of the knee in a ﬂare state and
with an American College of Rheumatology functional capacity classi-
ﬁcation I to III at baseline visit were eligible for randomization to either
celecoxib 200 mg qd or placebo in a 1:1 ratio. The previous treatment
durations of naproxen (at least 750 mg/d) and ibuprofen (at least 1200
mg/d) had to be a minimum of 2 weeks if failure was due to lack of
efﬁcacy and for any duration if failure was due to lack of tolerability. The
primary efﬁcacy variable in both trials was the change in the Patient's
Assessment of Arthritis Pain using a 100-mm visual analog scale (VAS)
at 6 weeks compared with baseline. The primary analysis compared
each trial separately for an intent-to-treat population. Safety assess-
ments included adverse events (AEs).
Results: In Study 1, 380 patients (mean age z 60 years) were
randomized. The majority of patients in the celecoxib and placebo
groups were female (62.1% and 58.9%, respectively) and white (71.6%
and 73.7%, respectively). At Week 6, the least squares mean (LSM)
decrease from baseline in the Patient's Assessment of Arthritis Pain
(VAS) in the celecoxib group was signiﬁcantly better than placebo (27.3
vs 14.9; P< 0.001). The proportion of patients reporting AEs was similar
in the celecoxib and placebo groups (all causality: 25.0% and 25.1%,
respectively; treatment-related: 6.4% and 5.3%, respectively). In Study 2,
388 patients (mean agez 58 years) were randomized. The majority of
patients in the celecoxib and placebo groups were female (71.3% and
64.2%, respectively) and just over one half were white (51.8% and 56.5%,
respectively). At Week 6, there was no signiﬁcant difference (P ¼ 0.183)
between the celecoxib (28.0 mm) and placebo (24.6 mm) groups in the
LSM change from baseline for the Patient's Assessment of Arthritis Pain
(VAS). The proportion of patients reporting AEs in the celecoxib and
placebo groups, respectively, was 22.2% and 26.2% for all-causality AEs;
6.2% and 11.5% for treatment-related AEs.
Conclusions: These 2 identically designed, concurrent, controlled trials
of celecoxib 200 mg qd vs placebo in patients with OA who previouslydid not respond to, or did not tolerate, treatment with naproxen and
ibuprofen, showed mixed results. For the primary end point of the
patient's assessment of pain, celecoxib was better than placebo in one
study but not in the other study. Celecoxib was well tolerated in both
trials. These discordant results highlight the challenges inherent in
treating OA of the knee in patients who failed previous nonsteroidal
anti-inﬂammatory drugs.484
UTILITY OF MECHANICAL ASSESSMENT IN KNEE OA MANAGEMENT
D.J. Hunter y, M. Williams z, A. Fuentes x, J. Makovey k. yUniv. of Sydney,
Royal North Shore Hosp., St Leonards, Australia; zRoyal North Shore
Hosp., Osteoarthritis Chronic Care Program, St Leonards, Australia;
x Imaging and Orthopedics Res. Lab., The CHUM Res. Ctr. - Hôpital Notre-
Dame, Montreal, QC, Canada; kUniv. of Sydney, St Leonards, Australia
Purpose: Biomechanical factors are known to be important in the
pathogenesis of OA however their assessment in clinical practice has
been limited due to need for sophisticated gait laboratory assess-
ments. Clinical decision making can be enhanced by access and
interpretation of useful information during the clinical encounter.
Theoretically osteoarthritis management (both the selection of inter-
vention and its intensity) can differ according to presenting clinical
features and clinician guidance. The knowledge relating to the deter-
mination of what biomechanical features are helpful in guiding ther-
apeutic decision making in osteoarthritis (OA) is limited. The purpose
of this investigation was to determine if knee kinematic measure-
ments were associated with other clinical factors associated with knee
OA such as quality of life, functional performance and depression and
therefore could be used in guiding clinical decision making in OA
management.
Methods: We selected a consecutive series of participants with knee
OA from the Osteoarthritis Chronic Care Program (OACCP). The OACCP
is a chronic disease rehabilitation program which aims to increase
functional capacity and manage co-morbidities, emphasising physical
activity and healthy weight management. In the OACCP, each partici-
pant is assessed by a multidisciplinary team. The team provides an
individualised intervention program in addition to education about OA
and any identiﬁed co-morbidities. This approach enables realistic goal
setting and optimal self-management. Data (including KOOS, DASS
(Depression anxiety stress scale), EQ5D quality of life measure, and
functional performance) is collected from assessments at 0, 12, 26 and
52 weeks into the OACCP and recorded on an electronic platform
provided. Key health outcomes for participants include the level of
pain experienced in the affected joint(s) and the ability to function in
activities of daily life. Three-dimensional (3D) knee kinematics data:
ﬂexion/extension, abduction/adduction and tibial internal / external
rotation (respectively in the frontal, sagittal, and transverse planes)
were recorded from each participant while walking on a treadmill at
a self-selected comfortable speed using a portable 3D knee kinematic
analyser, KneeKGTM. The 3D kinematics were recorded during two
gait trials of 25 sec. Non-parametric correlation and multiple regres-
sion analysis were performed to study an association between knee
kinematic and health outcome measures in knee OA OACCP
participants.
Results: 60 knees from 52 persons with knee OA were assessed. 52%
were female, their mean age was 68.6 years, mean BMI of 30.7kg/m2.
The total range of ﬂexion/extension motion (mean amplitude
49.29.8) in 90% of cohort was inferior compared to a typical walking
pattern. All 60 (100%) had limited ﬂexion excursion during loading
(Table 1). The amplitude of the adduction/abduction (mean 9.23.5)
was distributed among the patients with 15 (25%) being below, 16
(27%) within and 29 (48%) above the normal walking pattern (Figure
1). Limited ﬂexion/extension was associated with presence of
depression and anxiety (p<.01), reduced functional performance on
the TUG (p<.02) and impaired quality of life (activities p<.01). Higher
varus angle at initial contact was associated with impaired quality of
life (activities p<.01).
Conclusions: A portable kinematic assessment identiﬁed a high
frequency of mechanical abnormalities in a cohort of persons with knee
OA. The validity of these kinematic measures is supported by associa-
tions with impaired quality of life, reduced functional performance and
depression. This information was useful in guiding tailored and indi-
vidualised clinical care.
